sub:assertion { d:DB05779v:identifier "DB05779" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05779" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05779> ; dv:drugbank-id "DB05779" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description """Oglufanide disodium is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection. Oglufanide disodium was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005. Oglufanide disodium works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection."""@en ; dct:identifier "drugbank:DB05779" ; dct:title "oglufanide disodium"@en ; adv:Drug ; rdfs:label "oglufanide disodium [drugbank:DB05779]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05779> . }